Psychiatric News (1/29) reports, “Patients with treatment-resistant depression may only receive a modest, short-term benefit from using intranasal esketamine as an add-on treatment, according to a meta-analysis.” Additionally, “the analysis reveals almost no benefit from esketamine for suicidality compared with placebo.” The findings were published in the American Journal of Psychiatry.
Related Links:
— “Meta-Analysis Reveals Disappointing Efficacy for Esketamine in Depression, Suicidality, Psychiatric News, January 29, 2025